机械取栓中动脉内辅助药物的荟萃分析
结果显示联合治疗与良好功能结局可能性更高相关(RR 1.13,95%CI 1.03-1.24),90天死亡率更低(RR 0.82,95%CI 0.72-0.94),成功再通和症状性颅内出血无显著差异。
要点
- 机械取栓联合动脉内辅助药物可能改善功能结局并降低90天死亡率。
- 联合治疗未显著增加症状性颅内出血风险。
- 成功再通率在联合治疗与单纯取栓间无显著差异。
核心结论
- 在大血管闭塞急性缺血性卒中患者中,机械取栓时联合使用动脉内辅助药物可能获得更好的功能结局和更低的死亡率。
主要发现
- 联合治疗组良好功能结局的可能性更高(RR 1.13,95%CI 1.03-1.24)。
- 联合治疗组90天死亡率更低(RR 0.82,95%CI 0.72-0.94)。
- 两组成功再通率无显著差异(RR 1.02,95%CI 0.99-1.06)。
- 两组症状性颅内出血风险无显著差异(RR 1.13,95%CI 0.87-1.46)。
关键数值与推荐
- 联合治疗组1348例(29.4%),单纯取栓组3233例(70.6%)。
临床怎么用
- 对于大血管闭塞急性缺血性卒中接受机械取栓的患者,可考虑联用动脉内辅助药物以改善功能结局和降低死亡率,但需个体化评估。
局限性
- 纳入研究均为非随机观察性研究,证据等级有限,需随机对照试验进一步验证安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In patients with acute ischemic stroke with large vessel occlusion, the role of intra-arterial adjunctive medications (IAMs), such as urokinase, tPA (tissue-type plasminogen activator), or glycoprotein IIb/IIIa inhibitors, during mechanical thrombectomy (MT) has not been clearly established. We aim to evaluate the efficacy and safety of concomitant or rescue IAM for acute ischemic stroke with large vessel occlusion patients undergoing MT. METHODS: We searched Medline, Embase, and Cochrane Stroke Group Trials Register databases from inception until March 13, 2020. We analyzed all studies with patients diagnosed with acute ischemic stroke with large vessel occlusion in the anterior or posterior circulation that provided data for the two treatment arms, (1) MT+IAM and (2) MT only, and also reported on at least one of the following efficacy outcomes, recanalization and 90-day modified Rankin Scale, or safety outcomes, symptomatic intracranial hemorrhage and 90-day mortality. Data were collated in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Sixteen nonrandomized observational studies with a total of 4581 patients were analyzed. MT only was performed in 3233 (70.6%) patients, while 1348 (29.4%) patients were treated with both MT and IAM. As compared with patients treated with MT alone, patients treated with combination therapy (MT+IAM) had a higher likelihood of achieving good functional outcome (risk ratio, 1.13 [95% CI, 1.03-1.24]) and a lower risk of 90-day mortality (risk ratio, 0.82 [95% CI, 0.72-0.94]). There was no significant difference in successful recanalization (risk ratio, 1.02 [95% CI, 0.99-1.06]) and symptomatic intracranial hemorrhage between the two groups (risk ratio, 1.13 [95% CI, 0.87-1.46]). CONCLUSIONS: In acute ischemic stroke with large vessel occlusion, the use of IAM together with MT may achieve better functional outcomes and lower mortality rates. Randomized controlled trials are warranted to establish the safety and efficacy of IAM as adjunctive treatment to MT.
引用
- Chen VHE, Lee GKH, Tan CH, et al. Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis. Stroke. 2021. PMID: 33611941. doi:10.1161/STROKEAHA.120.031738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。